Michail I.
- Country
- Belgium
- Department
- Clinical Trial Conduct Unit
Research Overview
- Phase I Study of DS-1103a in Combination Therapy for Advanced HER2-Expressing or HER2-Mutated Solid Tumors
- EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
- Phase 2 Randomized Study of PF-07220060 and Letrozole Versus Letrozole in Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer
Data & Insights
Has run more than one trial at 224 of 486 partner sites.
Specializations
Breast Cancer Specialization
This investigator focuses extensively on treating various forms of hormone receptor-positive (HR+) breast cancer, with particular emphasis on HER2-negative breast cancer variants. Their research encompasses both early-stage and advanced disease states.
- Early-stage breast cancer treatment
- Advanced/metastatic breast cancer management
- Node-positive breast cancer
The investigator has significant experience in treating localized and metastatic forms of breast cancer.
Therapeutic Approaches
The investigator specializes in endocrine therapy combinations and novel therapeutic strategies for breast cancer treatment. Their work includes evaluation of targeted therapies and alternative treatment approaches.
- Adjuvant systemic treatments
- Neoadjuvant therapy
- Combination therapeutic strategies
Their expertise extends to personalized treatment approaches for different patient populations.
Advanced Cancer Research
The investigator works with unresectable locally-advanced cancers and explores treatments for patients with high-risk disease profiles. Their research includes innovative approaches for treating resistant or progressive disease.
- HER2-expressing tumors
- Hormone receptor-positive diseases
- Circulating tumor DNA assessment
Their work includes evaluation of treatment efficacy in various disease stages.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.